---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-034689"
form_type: "8-K"
ticker: "RCKT"
cik: "0001281895"
company_name: "ROCKET PHARMACEUTICALS, INC."
filed_at: "2026-08-27T20:06:27+00:00"
generated_at: "2026-08-27T20:07:31.263618+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Rocket Pharma adopts severance program; new CEO/GC/COO employment agreements

## Summary
- CEO Gaurav Shah gets $674,856 base salary, 60% target bonus; 15-month severance (non-CIC) and 18-month (CIC).
- GC Martin Wilson gets $547,313 base salary, 45% target bonus; 12-month severance, plus 12-month CIC terms.
- COO Christopher Stevens amendment: 12-month base salary severance, CIC terms include target bonus and prorated bonus.
- New severance program covers all eligible US employees; CEO gets 15/18 months, ELT 12 months, VPs 6/9 months, etc.

## SEC filing metadata
- accession: 0001140361-26-034689
- form_type: 8-K
- ticker: RCKT
- cik: 0001281895
- company_name: ROCKET PHARMACEUTICALS, INC.
- filed_at: 2026-08-27T20:06:27+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1281895/000114036126034689/0001140361-26-034689-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1281895/000114036126034689/ef20081170_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-034689
- JSON: https://secwatch.observer/filing/0001140361-26-034689.json
- Plain text: https://secwatch.observer/filing/0001140361-26-034689.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.